MEI Pharma, Inc.
NASDAQ:MEIP
Overview | Financials
Company Name | MEI Pharma, Inc. |
Symbol | MEIP |
Currency | USD |
Price | 3.06 |
Market Cap | 20,388,352 |
Dividend Yield | 55.38% |
52-week-range | 2.61 - 7.87 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. David M. Urso B.A., Esq., J.D. |
Website | https://www.meipharma.com |
An error occurred while fetching data.
About MEI Pharma, Inc.
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD